Bayer has experienced substantial losses recently, with its
stocks sinking due to a $1.5bn Roundup verdict and termination of the asundexian trial. The firm's shares dropped to an 18-year low, although it saw a surge following a
Monsanto Appeal win. Despite this uptick, Bayer faces ongoing challenges, particularly with its notorious Roundup product and after its blood thinner drug setback. Yet it still plans US expansion, ignores breakup speculations and focuses on a management revamp. A simulated
M&A has cast doubt on any quick fixes for the company’s struggles. Crucially,
Bayer lost an appeal in the Roundup case, and is slashing its dividend as a strategy to grapple with these Roundup difficulties. However, it scored a major court win in a PCB case, and further decided to acquire BridgeBio's Cardiovascular Drug. Investors have flagged the long-term upside, although the firm faces challenges across its pipeline and recent drug trial failures.
Bayer's shares price target remains intact despite such near-term headwinds, but it's a case for patient investors.
BAYER Stocks News Analytics from Tue, 22 Aug 2023 07:00:00 GMT to Thu, 11 Jul 2024 07:00:53 GMT -
Rating -5
- Innovation -2
- Information 8
- Rumor -3
